Generali Investments Towarzystwo Funduszy Inwestycyjnych Has $959,000 Stock Position in STAAR Surgical (NASDAQ:STAA)

Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in STAAR Surgical (NASDAQ:STAA) by 9.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,500 shares of the medical instruments supplier’s stock after purchasing an additional 3,500 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych owned approximately 0.08% of STAAR Surgical worth $959,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Van ECK Associates Corp lifted its stake in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 393 shares in the last quarter. Creative Planning lifted its stake in STAAR Surgical by 8.0% in the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 408 shares in the last quarter. LMR Partners LLP lifted its stake in STAAR Surgical by 2.2% in the 3rd quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock valued at $1,290,000 after acquiring an additional 743 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in STAAR Surgical in the 3rd quarter valued at approximately $37,000. Finally, Quarry LP bought a new stake in STAAR Surgical in the 3rd quarter valued at approximately $50,000. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on STAA shares. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday. BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Stephens reiterated an “equal weight” rating and set a $28.00 target price on shares of STAAR Surgical in a research report on Wednesday, February 12th. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group dropped their price objective on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical currently has an average rating of “Hold” and an average target price of $26.86.

STAAR Surgical Trading Up 3.5 %

Shares of STAA stock opened at $17.69 on Friday. The stock has a market cap of $871.69 million, a price-to-earnings ratio of -43.15 and a beta of 0.62. The stock has a 50-day moving average of $21.85 and a 200-day moving average of $27.59. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Insiders Place Their Bets

In related news, major shareholder Broadwood Partners, L.P. acquired 53,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were bought at an average price of $24.24 per share, with a total value of $1,296,840.00. Following the transaction, the insider now directly owns 10,821,931 shares of the company’s stock, valued at $262,323,607.44. This trade represents a 0.50 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders acquired 402,024 shares of company stock worth $6,936,904. 1.00% of the stock is owned by corporate insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.